Skip to main content

Table 1 Baseline charasteristics and medicatoins of the participants

From: Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance

  Placebo (n = 51) EMPA (n = 51) P value
Age (years) 58.1 ± 9.71 57.4 ± 12.3 0.778
Male/(female) 41 (10) 38 (13) 0.636
Baseline medication
 Slfonylureas 11 10 1
 Metformin 12 12 1
 α-GI 8 7 1
 ARB 16 17 0.915
 CCB 10 10 1
 Statins 17 16 1
 Fibrates 9 10 0.879
  1. Data were expressed as mean ± standard deviation
  2. α-GI α-glicosidase inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker